Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245096 | 0.95 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR1ADRD2 | |
| SCHEMBL3245091 | 0.81 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HTR1ADRD2 | |
| SCHEMBL4384644 | 0.81 | TDP1 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22099626 | 0.81 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL3173969 | 0.81 | ABCB1 (0.68) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL3243957 | 0.81 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR1ADRD2 | |
| SCHEMBL10675568 | 0.80 | ABCB1 (0.67) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL5059542 | 0.79 | HTR7 (0.58) | SLC6A4HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3246821 | 0.79 | DRD1 (0.58) | SLC6A4SLC6A2SLC6A3DRD2DRD3 | |
| SCHEMBL3655159 | 0.78 | HRH3 (0.61) | SLC6A4SLC6A2SLC6A3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | SLC6A4 314/4885SLC6A2 136/4885SLC6A3 597/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | SLC6A4 3626/4885SLC6A2 4136/4885SLC6A3 3349/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | SLC6A4 3715/4885SLC6A2 4192/4885SLC6A3 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.